Related Experiment Video
Updated: Dec 29, 2025

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification
Abigail Healy1, Joshua M Berus1, Jared L Christensen1
1From the Department of Medicine (Section of Cardiovascular Medicine) and Research Services, Providence VA Medical Center, RI; and Department of Internal Medicine (Section of Cardiovascular Medicine), Alpert Medical School at Brown University, Providence, RI.
Insights
Statins may increase coronary calcification by activating a macrophage Rac1-IL-1β pathway. This mechanism involves increased active Rac1 and IL-1β secretion, potentially impacting atherosclerotic plaque stability.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Atherosclerosis Research
Background:
- Calcification in atherosclerotic plaque is linked to cardiovascular risk, though higher density may indicate stability.
- Statins (3-hydroxy-3-methylglutaryl coenzymeA reductase inhibitors) reduce cardiovascular events but their effect on plaque calcium composition is unclear.
- A macrophage Rac (Ras-related C3 botulinum toxin substrate)-IL-1β (interleukin-1 beta) signaling axis was identified as a key mechanism in atherosclerotic calcification.
Purpose of the Study:
- To investigate the impact of statin therapy on the macrophage Rac-IL-1β signaling axis in atherosclerotic calcification.
- To elucidate the molecular mechanisms underlying statin-mediated effects on plaque calcium composition.
Main Methods:
- Analysis of statin's association with coronary calcification in high-risk patients.
- Investigation of statin's effect on Rac1 activation, NF-κB activation, and IL-1β secretion in primary monocytes/macrophages.
- Utilizing an animal model of calcific atherosclerosis to assess statin's impact on myeloid Rac1 activation and plaque calcification.
Main Results:
- Statin therapy was independently associated with elevated coronary calcification.
- Statins disrupt the Rac1-RhoGDI complex, increasing active Rac1 in macrophages, which can be rescued by geranylgeranyl diphosphate.
- Statin-treated macrophages showed increased NF-κB activation, IL-1β mRNA, and Rac1-dependent IL-1β secretion.
- In an animal model, statins increased atherosclerotic calcification via a myeloid Rac1-dependent pathway, associated with increased IL-1β and osteogenic markers.
Conclusions:
- Statin therapy is linked to increased atherosclerotic calcification.
- Statins increase calcification by disinhibiting the macrophage Rac1-IL-1β signaling axis.
- This pathway involves increased active Rac1 and IL-1β secretion, contributing to plaque calcification.
Objective:
Calcification of atherosclerotic plaque is traditionally associated with increased cardiovascular event risk; however, recent studies have found increased calcium density to be associated with more stable disease. 3-hydroxy-3-methylglutaryl coenzymeA reductase inhibitors or statins reduce cardiovascular events. Invasive clinical studies have found that statins alter both the lipid and calcium composition of plaque but the molecular mechanisms of statin-mediated effects on plaque calcium composition remain unclear. We recently defined a macrophage Rac (Ras-related C3 botulinum toxin substrate)-IL-1β (interleukin-1 beta) signaling axis to be a key mechanism in promoting atherosclerotic calcification and sought to define the impact of statin therapy on this pathway. Approach and Results: Here, we demonstrate that statin therapy is independently associated with elevated coronary calcification in a high-risk patient population and that statins disrupt the complex between Rac1 and its inhibitor RhoGDI (Rho GDP-dissociation inhibitor), leading to increased active (GTP bound) Rac1 in primary monocytes/macrophages. Rac1 activation is prevented by rescue with the isoprenyl precursor geranylgeranyl diphosphate. Statin-treated macrophages exhibit increased activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), increased IL-1β mRNA, and increased Rac1-dependent IL-1β protein secretion in response to inflammasome stimulation. Using an animal model of calcific atherosclerosis, inclusion of statin in the atherogenic diet led to a myeloid Rac1-dependent increase in atherosclerotic calcification, which was associated with increased serum IL-1β expression, increased plaque Rac1 activation, and increased plaque expression of the osteogenic markers, alkaline phosphatase and RUNX2 (Runt-related transcription factor 2).
Conclusions:
Statins are capable of increasing atherosclerotic calcification through disinhibition of a macrophage Rac1-IL-1β signaling axis.
More Related Videos
Related Concept Videos
Atherosclerosis I: Introduction
Inflammation
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease II: Pathophysiology
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...

